Express News | Compugen Reports Publication Of Paper In Cancer Immunology Research Demonstrating Therapeutic Potential Of COM503
Moomoo 24/7Apr 10 07:02 ET
Compugen to Participate in Two Upcoming Investor Conferences
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
PR NewswireApr 3 07:00 ET
Truist Financial Reaffirms Their Buy Rating on Compugen (CGEN)
TipRanksMar 15 07:08 ET
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) Is a Great Choice
Yahoo FinanceMar 12 12:00 ET
Compugen Selected for Two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
PR NewswireMar 11 07:00 ET
Compugen Is Maintained at Buy by Truist Securities
Compugen Is Maintained at Buy by Truist Securities
Dow JonesMar 8 09:25 ET
Express News | Truist Securities Maintains Buy on Compugen, Raises Price Target to $5
Moomoo 24/7Mar 8 09:15 ET
Compugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/08/2024 88.68% Truist Securities $4 → $5 Maintains Buy 12/19/2023 50.94% Stifel $3 → $4 Maintains Buy 0
BenzingaMar 8 09:13 ET
Analysts Offer Insights on Healthcare Companies: Cigna (CI), Compugen (CGEN) and OrthoPediatrics (KIDS)
TipRanksMar 8 07:20 ET
Compugen Ltd. (NASDAQ:CGEN) Held Back By Insufficient Growth Even After Shares Climb 26%
Compugen Ltd. (NASDAQ:CGEN) shares have continued their recent momentum with a 26% gain in the last month alone. The annual gain comes to 258% following the latest surge, making investors sit up an
Simply Wall StMar 8 05:54 ET
Compugen to Present Data Reflecting Its Diversified Immuno-Oncology Pipeline at AACR 2024
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
PR NewswireMar 6 07:00 ET
Earnings Call Summary | Compugen(CGEN.US) Q4 2023 Earnings Conference
The following is a summary of the Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript:Financial Performance:Compugen had approximately $51.1 million in cash, cash equivalents, restricted cash, and c
moomoo AIMar 5 15:05 ET · Conference Call
Express News | Compugen Shares Are Trading Lower After the Company Reported Worse-than-expected Q4 EPS Results
Moomoo 24/7Mar 5 11:24 ET
Regenxbio, Quoin Pharmaceuticals, Renalytix Among Healthcare Movers
Seeking AlphaMar 5 10:02 ET
Interleukin-18 (IL-18) Inhibitor Market Research Report 2024: Insight Into Pipeline Landscape Featuring AB2 Bio, Simcha Therapeutics, GSK, Novartis, Olatec Therapeutics, Compugen, Lassen Therapeutics - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.In the rapidly advancing field of medical research,
BusinesswireMar 5 07:25 ET
Compugen: Q4 Earnings Snapshot
BarchartMar 5 07:16 ET
Earnings Flash (CW9) COMPUGEN Posts Q4 EPS $0.11
07:05 AM EST, 03/05/2024 (MT Newswires) -- Earnings Flash (CW9) COMPUGEN Posts Q4 EPS $0.11
MT NewswiresMar 5 07:05 ET
Compugen Had $51.1M in Cash, Cash Equivalents, Restricted Cash, and Cash Investments as of Dec 31 >CGEN.TV
Compugen Had $51.1M in Cash, Cash Equivalents, Restricted Cash, and Cash Investments as of Dec 31 >CGEN.TV
Dow JonesMar 5 07:04 ET
Compugen 4Q EPS 11c >CGEN.TV
Compugen 4Q EPS 11c >CGEN.TV
Dow JonesMar 5 07:03 ET
Compugen: Solid Balance Sheet With Extended Cash Runway Expected to Fund Ops Into 2027 >CGEN.TV
Compugen: Solid Balance Sheet With Extended Cash Runway Expected to Fund Ops Into 2027 >CGEN.TV
Dow JonesMar 5 07:03 ET
No Data
No Data